Table 2.
Clinical characteristics in patients who experienced a relapse.
| Cause of discontinuation | Relapses (n = 12) | ||
|---|---|---|---|
| CR (n = 3) | SD/PD (n = 2) | AEs (n = 7) | |
| Age | |||
| <65 years | 3 | 2 | 3 |
| >65 years | 0 | 0 | 4 |
|
| |||
| Sex | |||
| Men | 2 | 1 | 2 |
| Women | 1 | 1 | 5 |
|
| |||
| BRAF status | |||
| Mutant | 2 | 1 | 3 |
| Wild type | 1 | 1 | 4 |
|
| |||
| First-line treatment | |||
| Yes | 1 | 1 | 3 |
| No | 2 | 1 | 4 |
|
| |||
| Prior ipilimumab | |||
| Yes | 2 | 0 | 3 |
| No | 1 | 2 | 4 |
|
| |||
| Prior BRAF ± MEK inhibitor | |||
| Yes | 1 | 1 | 2 |
| No | 2 | 1 | 5 |
|
| |||
| Radiotherapy while on treatment | |||
| Yes | 2 | 0 | 2 |
| No | 1 | 2 | 5 |
|
| |||
| TOT | |||
| <12 months | 0 | 1 | 5 |
| >12 months | 3 | 1 | 2 |
|
| |||
| Relapse site | |||
| Known sites | 1 | 1 | 4 |
| New lesions | 2 | 1 | 3 |